Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial
Status:
Recruiting
Trial end date:
2024-03-13
Target enrollment:
Participant gender:
Summary
This is a updated trial of NCT04188860 as a multi-center study. For recurrent or persistent
advanced cervical cancer patients, the first-line chemotherapy was based on platinum.
However, if they were refractory to platinum-based chemotherapy, there were no other more
effective medications or treatment. The marketing of anti-PD-1 antibody has provided an
opportunity of curative management. This single arm, open, phase II trial would recruit 122
eligible patients. A combination of anti-PD-1 antibody camrelizumab and albumin-bound
paclitaxel would be given for all patients. The primary end is overall response rate (ORR).
The second ends include progression-free survival, overall survival, disease control rate,
remission duration, and adverse events. A molecular testing, mainly consisting of genomic
analysis, will be carried in the oncologic tissues.